Related Experiment Video
Updated: Jan 28, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.0K
Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection
Tine Bajec1, Neža Žorž1, Sabina Ugovšek1
1Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Journal of Cardiovascular Development and Disease
|January 27, 2026
Summary
Vericiguat added to guideline-directed medical therapy (GDMT) shows promise for improving heart function and structure in patients with heart failure with reduced ejection fraction (HFrEF). This study suggests vericiguat may promote reverse myocardial remodeling in HFrEF patients experiencing recent worsening.
Area of Science:
- Cardiology
- Pharmacology
- Heart Failure Research
Background:
- Vericiguat is known to reduce cardiovascular events in patients with recently worsened heart failure with reduced ejection fraction (HFrEF).
- The impact of vericiguat on cardiac remodeling in these patients is not fully understood.
Purpose of the Study:
- To investigate whether adding vericiguat to guideline-directed medical therapy (GDMT) can induce reverse myocardial remodeling in patients with HFrEF and recent worsening.
- To assess changes in cardiac structure and function following vericiguat treatment.
Main Methods:
- A prospective, non-randomized, single-center study.
- 34 consecutive patients with HFrEF and recent worsening, on stable GDMT, were enrolled.
- Clinical, biochemical, and echocardiographic assessments were conducted at baseline and 6 months.
Main Results:
- Significant improvements in right ventricular systolic function (TAPSE) and left ventricular outflow tract velocity-time integral (LVOT VTI).
- Observed reductions in right ventricular internal diameter (RVIDd) and left ventricular end-systolic volume (LVESV), indicating reverse remodeling.
- Significant decrease in NT-proBNP levels, a marker of heart failure severity.
Conclusions:
- The addition of vericiguat to GDMT in patients with HFrEF and recent worsening may be linked to reverse myocardial remodeling.
- Vericiguat demonstrates potential benefits beyond reducing major adverse cardiovascular events, by improving cardiac structure and function.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
313
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313
01:17Pathophysiology of Heart Failure
3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
01:27Heart Failure I: Introduction
829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
01:29Heart Failure II: Pathophysiology
855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
01:22Heart Failure Drugs: Diuretics
935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
01:30Heart Failure V: Medical Management
267
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
267